| Dr Retna A Billano, MD | |
|
4325 Dolly Ridge Road, Vestavia, AL 35243 | |
| (205) 591-2169 | |
| (205) 591-0815 |
| Full Name | Dr Retna A Billano |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 48 Years |
| Location | 4325 Dolly Ridge Road, Vestavia, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033208541 | NPI | - | NPPES |
| 51169838 | Other | AL | BCBS PROVIDER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | 11134 (Alabama) | Primary |
| Entity Name | Retna A Billano, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831555218 PECOS PAC ID: 9931403805 Enrollment ID: O20160212002026 |
News Archive
"As WHO prepares for reform, it is also adjusting to a new financially constrained environment. WHO's STOP TB department, like others, has to downsize and refocus its activities. With increasing demand for guidance, technical support, and capacity-building in countries, the STOP TB department and partnership will have to do more with less in the future," a Lancet editorial states.
The Economist's "Graphic Detail" blog features an infographic depicting the probability of dying from a non-communicable disease by country. "You are more likely to be killed by a non-communicable disease (NCD), like cancer or heart disease, than anything else," the blog notes.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
A new miniature, hand-held microscope may allow more precise removal of brain tumors and an easier recognition of tumor locations during surgery.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Retna A Billano, MD 4325 Dolly Ridge Road, Vestavia, AL 35243 Ph: (205) 591-2169 | Dr Retna A Billano, MD 4325 Dolly Ridge Road, Vestavia, AL 35243 Ph: (205) 591-2169 |
News Archive
"As WHO prepares for reform, it is also adjusting to a new financially constrained environment. WHO's STOP TB department, like others, has to downsize and refocus its activities. With increasing demand for guidance, technical support, and capacity-building in countries, the STOP TB department and partnership will have to do more with less in the future," a Lancet editorial states.
The Economist's "Graphic Detail" blog features an infographic depicting the probability of dying from a non-communicable disease by country. "You are more likely to be killed by a non-communicable disease (NCD), like cancer or heart disease, than anything else," the blog notes.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
A new miniature, hand-held microscope may allow more precise removal of brain tumors and an easier recognition of tumor locations during surgery.
› Verified 5 days ago